1. Home
  2. INDP vs ASMB Comparison

INDP vs ASMB Comparison

Compare INDP & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$3.18

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$22.55

Market Cap

512.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
ASMB
Founded
2000
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
512.1M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
INDP
ASMB
Price
$3.18
$22.55
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $51.20
AVG Volume (30 Days)
211.2K
★ 242.8K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.78
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.11
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$19.20
52 Week High
$5.96
$39.65

Technical Indicators

Market Signals
Indicator
INDP
ASMB
Relative Strength Index (RSI) 50.79 54.82
Support Level $2.17 $21.80
Resistance Level $3.71 $23.83
Average True Range (ATR) 0.34 1.33
MACD -0.02 0.41
Stochastic Oscillator 51.34 74.42

Price Performance

Historical Comparison
INDP
ASMB

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: